Interventional Oncology Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Interventional Oncology Market size was estimated at USD 2,930 million in 2024 and is projected to reach USD 5,601.6 million in 2031 at a CAGR of 9.7 % during the forecast period 2025-2031.

The interventional oncology market involves medical procedures that use minimally invasive techniques to treat cancer through targeted therapies. This field includes treatments such as tumor ablation, embolization, and percutaneous biopsy, typically guided by imaging technologies like CT scans, MRI, or ultrasound. Interventional oncology offers patients an alternative to traditional surgery, with advantages such as reduced recovery times, less pain, and lower risk of complications. The increasing incidence of cancer worldwide, combined with advancements in imaging and medical devices, has significantly contributed to the growth of this market.

The scope of the interventional oncology market extends across various types of cancer, including liver, lung, prostate, and kidney cancers, with treatments tailored to the location and size of the tumor. It is applicable in both curative and palliative care settings, offering solutions for patients who may not be candidates for conventional surgery due to their health condition or the complexity of the cancer. The market includes hospitals, outpatient clinics, and specialized oncology centers, where interventional radiologists perform these procedures. With the rise in cancer cases and the need for more effective and less invasive treatments, the scope of interventional oncology continues to expand globally.

Key trends in the interventional oncology market include the increasing adoption of image-guided techniques and the development of new, advanced tools that improve treatment precision and patient outcomes. Innovations in embolization techniques, such as drug-eluting beads and the use of artificial intelligence for better treatment planning, are also gaining traction. Furthermore, there is growing interest in combination therapies, where interventional oncology is used alongside other treatments like chemotherapy or immunotherapy to improve overall effectiveness. The trend towards personalized medicine is also shaping the market, with treatments tailored to individual patient profiles for optimized results.

The growth drivers of the interventional oncology market are largely influenced by the rising cancer prevalence, the demand for minimally invasive treatments, and the advancements in imaging and medical device technologies. An aging global population, along with increasing awareness of cancer treatments, has led to greater demand for more effective cancer care options. Additionally, the expansion of healthcare infrastructure, especially in emerging markets, and increasing investment in research and development for new therapies are fuelling the market’s expansion. The ability of interventional oncology to offer less invasive, cost-effective treatments is another key factor driving its adoption in cancer care worldwide.

Delvens Industry Expert's Standpoint

Experts in the Interventional Oncology Market highlight several key trends driving growth and innovation. The interventional oncology market focuses on minimally invasive procedures used to treat cancer, such as tumor ablation, embolization, and biopsy, often guided by advanced imaging technologies. It caters to various cancer types, providing both curative and palliative treatment options, especially for patients who are not candidates for traditional surgery. The market is driven by the rising global incidence of cancer, advancements in imaging and medical devices, and a shift towards less invasive, personalized treatments. Key trends include the adoption of image-guided techniques, innovations in embolization, and combination therapies, while drivers such as an aging population, increased awareness, and the demand for cost-effective care continue to fuel market growth.

Market Portfolio

Key Findings

• Ablation therapies lead the market with minimally invasive approaches like radiofrequency, microwave, cryoablation, and laser ablation, which precisely destroy tumors while preserving nearby healthy tissue. These methods deliver faster recovery, reduced discomfort, and fewer complications than traditional surgery or radiation, meeting the growing global demand for innovative cancer treatments as case numbers rise.

• Embolization therapies are positioned for notable growth by cutting off blood flow to tumors, proving especially effective for conditions like liver cancer. Offering quicker recovery and lower risks compared to conventional surgery, these outpatient procedures appeal to patients and providers alike, reducing expenses and hospital time in line with the push for patient-centric healthcare.

• Vascular interventions hold the highest revenue share, driven by procedures such as transarterial chemoembolization (TACE) and radioembolization (TARE), which capitalize on minimally invasive technology and the increasing prevalence of liver cancer. These techniques provide targeted tumor treatment with less toxicity and better results, supported by an aging population and ongoing advancements in the field.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as Rising Prevalence of Cancer, Advancements in Technology, Increasing Demand for Minimally Invasive Treatments, Aging Population, Rising Healthcare Expenditure, Growing Awareness of Interventional Oncology, Favorable Reimbursement Policies, Increased Focus on Personalized Medicine, Expansion of Interventional Oncology Centers, Technological Partnerships and Collaborations have triggered the Interventional Oncology Market in the region.

Regional Analysis

North America to Dominate the Market

• North America holds a commanding position in the global market, capturing a share of around 35%, driven by factors such as the presence of leading market players, substantial healthcare spending, widespread awareness of minimally invasive techniques, a supportive regulatory environment, and a high incidence of cancer. In Canada, cancer ranks as the top cause of death, with projections indicating a significant number of new diagnoses annually, fueling the need for advanced interventional oncology solutions and propelling market expansion in the region.

• The U.S. market is poised for notable growth, supported by the presence of key industry players, a favorable regulatory framework, intensified research and development efforts, and heightened government campaigns to raise cancer awareness. Funding initiatives, such as those from the Society of Interventional Radiology Foundation, which allocated substantial resources to projects focused on embolization and interventional oncology research, are expected to spur innovative therapies and enhance patient outcomes, further strengthening the market.

• Europe is set to experience robust growth, propelled by an increasing cancer prevalence, a growing emphasis on minimally invasive cancer treatments, an aging population, and enhanced government efforts. Reports indicate millions of new cancer cases across the EU annually, alongside a rising number of cancer-related deaths, underscoring the escalating demand for interventional oncology solutions and driving market progress in the region.

• Asia Pacific is expected to see the most rapid growth, fueled by a high cancer burden, improving healthcare infrastructure, and rising efforts to promote interventional oncology procedures. Collaborative initiatives, such as those between the U.S. and India to bolster access to oncology trials, highlight the region's focus on overcoming regulatory challenges and expanding the adoption of advanced cancer care solutions, significantly boosting market development.

Competitive Landscape

• Medtronic plc
• Boston Scientific Corporation
• Johnson & Johnson (Ethicon)
• Baxter International Inc.
• Cook Medical
• C.R. Bard Inc. (Acquired by BD)
• AngioDynamics Inc.
• Stryker Corporation
• B. Braun Melsungen AG
• Terumo Corporation
• Siemens Healthineers
• GE Healthcare

Recent Developments

• In August 2022, Boston Scientific Corporation acquired Obsidio, Inc., enhancing its interventional oncology and embolization portfolio by incorporating Gel Embolic Material (GEM) technology. This addition provides a unique solution for both patients and physicians.

• In July 2021, Terumo Europe entered into a Memorandum of Understanding (MoU) with the University Medical Center Utrecht (UMC Utrecht) to expand their collaboration, aiming to advance education and innovation in the development of effective interventional oncology solutions.

• In July 2020, Terumo Corporation acquired Quirem Medical, a healthcare startup based in the Netherlands, to strengthen its interventional oncology capabilities. The acquisition brings three integrated products—QuiremScout, QuiremSpheres, and Q-Suite—into the company’s portfolio, enabling physicians to deliver personalized treatments to patients.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Interventional Oncology Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope